Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72116 | 1.00 | ITGB1 (0.42) | ITGB1ITGA4ACKR3MAOBCA12 | |
| SCHEMBL72391 | 0.91 | ITGB1 (0.46) | ITGB1ITGA4ACKR3MAOBCA12 | |
| SCHEMBL72390 | 0.91 | ITGB1 (0.46) | ITGB1ITGA4ACKR3MAOBCA12 | |
| SCHEMBL71928 | 0.91 | ITGB1 (0.44) | ITGB1ITGA4ACKR3MAOBCA12 | |
| SCHEMBL71927 | 0.91 | ITGB1 (0.44) | ITGB1ITGA4ACKR3MAOBCA12 | |
| SCHEMBL72573 | 0.90 | ITGB1 (0.47) | ITGB1ITGA4ACKR3MAOB | |
| SCHEMBL72572 | 0.90 | ITGB1 (0.47) | ITGB1ITGA4ACKR3MAOB | |
| SCHEMBL72078 | 0.90 | ITGB1 (0.43) | ITGB1ITGA4ACKR3MAOB | |
| SCHEMBL73718 | 0.89 | ITGB1 (0.46) | ITGB1ITGA4ACKR3MAOB | |
| SCHEMBL71354 | 0.89 | ITGB1 (0.44) | ITGB1ITGA4ACKR3MAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGB1 16/4885ITGA4 3/4885ACKR3 1177/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ITGB1 13/4885ITGA4 3/4885ACKR3 1103/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGB1 22/4885ITGA4 3/4885ACKR3 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.